

G1070-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kenneth W. BATCHELOR

Serial No.: 08/405,120

Art Unit: 1202

Filed: March 16, 1995

Examiner: D. Daus

Allowed: May 23, 1996

Batch No.: A22

Title: ANDROSTENONE DERIVATIVE

Assistant Commissioner of Patents and Trademarks

Washington, D.C. 20231

**Transmittal of Issue Fee PTO 85(b) and 85(c)
With Certificate of Assignee's Name Change**


Sir:

Enclosed is payment of the Issue Fee PTO 85(b) for this application
which was allowed May 23, 1996

Also enclosed is PTO 85(c) authorizing Examiner to charge any fee which
might be due as a result of payment of the Issue Fee and for the order of 20 soft
copies of the patent to issue, or to credit any overcharge, to applicant's **Deposit
Account No. 07-1392.**

Also attached is a North Carolina Certificate of Name Change for Glaxo
Inc. to Glaxo Wellcome Inc.

Respectfully submitted,




Robert H. Brink
Attorney of Record
Registration No. 36,094

Glaxo Wellcome Inc.
Five Moore Drive
Research Triangle Park
North Carolina 27709
(919) 483-6983

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Date: July 31, 1996


Rosalie Germano